Designed for optimal health and wellness
It helps protect cellular structures and genetic material from damage, supporting optimal cellular function
Healthcare providers should maintain open communication about all treatments patients are using and provide evidence-based guidance prioritizing interventions with established safety and efficacy profiles
Growth factor amplification: The growth factors influenced by each peptide overlap partially, creating potential amplification effects
Peer-reviewed RCT data in human tendon injury populations has not yet been published at scale
A 2026 UK review of how HGF activates repair Schwann cells (Ko 2018, Scientific Reports ), the 2021 rat sciatic-nerve study where Dihexa + stem cells improved motor recovery, the VM202 / Engensis HGF gene-therapy Phase 3 in painful diabetic peripheral neuropathy (results posted Jan 2025), chemotherapy-induced neuropathy (CIPN) and the duloxetine question, and the 2026 AthiraLeonaBio pivot taking the oral HGF/MET modulator ATH-1105 into ALS with an honest account of why Dihexa still has zero human neuropathy data Read the full review Neuroscience 27 May 2026 Dihexa for Migraine & Chronic Migraine: The 2026 UK Review Rigorous 2026 UK review of Dihexa for migraine and chronic migraine
